Ganesh Moorthy

October 17, 2026

Japan funds new GlobalFoundries plants; US increases stake. Japan is investing up to $21 billion in new GlobalFoundries chip plants in New York, while the Trump administration doubled its stake in the company. Wedbush noted that long-term earnings from this US-Japan deal could be bullish, though shares recently retreated as investors weighed the impact. This development highlights a significant shift in semiconductor manufacturing toward US onshoring.

October 16, 2026

Ralliant (RAL) receives analyst upgrades and price target changes. Ralliant announced the date for its third‑quarter 2026 earnings release and conference call. RBC Capital kept its sector‑perform rating but lowered the price target to $72, while Seaport Global upgraded the stock to Buy with an $88 target. The mixed analyst actions suggest both caution over higher costs and optimism about growth opportunities. The stock is near its 52‑week high and below the average analyst target of $79.18.

October 17, 2026

SiTime faces mixed analyst views amid broader chip sector decline. Recent coverage shows SiTime being called expensive by a prominent market commentator, while other analysts highlight rapid total addressable market growth and a potential earnings boost from Renesas' TPD business. At the same time, chip stocks overall have been pressured by AI investment worries and higher financing rates. The contrasting opinions and sector backdrop provide context for SiTime's current market perception.

October 9, 2026

Celanese Sets Q3 Earnings Call for November 3, 2026. Celanese has announced it will hold its third-quarter earnings conference call on November 3, 2026. The company is also mentioned in a new industry report on thermo compression forming, which highlights its role in advanced manufacturing. With the stock trading near its 52-week low, upcoming earnings results may provide clarity on the company's performance.

October 17, 2026

Microchip Tech partners with Elektrobit for automotive solutions. Microchip Technology has announced a collaboration with Elektrobit to develop pre-integrated AUTOSAR solutions for next-generation automotive platforms. The company also expanded its space power portfolio with a new radiation-tolerant converter. These moves align with broader sector rebounds and positive analyst views on demand and pricing, though the stock currently trades well below its average analyst target.

October 12, 2026

Roche presents new Phase III data and FDA approval. Roche reported new one-year Phase III data for vamikibart in treating uveitic macular edema, a condition causing vision loss. Additionally, the FDA approved Tecentriq for adjuvant treatment of stage III colon cancer. These developments reflect ongoing progress in the company's clinical pipeline and regulatory approvals.